GABA Stock Overview
Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Gabather AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.00 |
| 52 Week High | kr4.96 |
| 52 Week Low | kr0.79 |
| Beta | 0.36 |
| 1 Month Change | 21.28% |
| 3 Month Change | 79.73% |
| 1 Year Change | -57.46% |
| 3 Year Change | -63.06% |
| 5 Year Change | -85.65% |
| Change since IPO | -89.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| GABA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 26.3% | 2.6% | 0.1% |
| 1Y | -57.5% | 54.9% | 11.2% |
Return vs Industry: GABA underperformed the Swedish Pharmaceuticals industry which returned 54.9% over the past year.
Return vs Market: GABA underperformed the Swedish Market which returned 11.2% over the past year.
Price Volatility
| GABA volatility | |
|---|---|
| GABA Average Weekly Movement | 30.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.5% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: GABA's share price has been volatile over the past 3 months.
Volatility Over Time: GABA's weekly volatility has increased from 21% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 3 | Michael-Robin Witt | www.gabather.com |
Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer’s disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease.
Gabather AB (publ) Fundamentals Summary
| GABA fundamental statistics | |
|---|---|
| Market cap | kr36.10m |
| Earnings (TTM) | -kr9.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs GABA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GABA income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr9.44m |
| Earnings | -kr9.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GABA perform over the long term?
See historical performance and comparison